Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3075-3083

  Slater, J L ^a   Howard, S J ^a   Sharp, A ^a   Goodwin, J ^a   Gregson, L M ^a   Alastruey Izquierdo, A ^b   Arendrup, M C ^c   Warn, P A ^a   Perlin, D S ^b   Hope, W W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FKS1 PROTEIN; FUNGAL PROTEIN; MICAFUNGIN; SERINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS GROWTH; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INVASIVE CANDIDIASIS; MALE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GENOTYPE; HUMANS; LIPOPEPTIDES; MALE; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 79959192938     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01686-10     Document Type: Article

References (22)

1. Arendrup, M. C., et al. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
2. Arendrup, M. C., et al. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and Isosensitest media. Antimicrob. Agents Chemother. 54:426-439.
3. Baixench, M. T., et al. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
4. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3(28). Clinical and Laboratory Standards Institute, Wayne, PA.
6. D'Argenio, D. Z., A. Schumitzky, and X. Wang. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
7. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. (Pubitemid 37222342)
8. European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
9. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
10. Gudlaugsson, O., et al. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
11. Gumbo, T., et al. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331.
12. Kuse, E. R., et al. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527.
13. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. Proc. 14th IEEE Computer Soc.
14. Louie, A., et al. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068.
15. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
16. Pappas, P. G., et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
17. Park, S., et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
18. Pfaller, M. A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
19. Pfaller, M. A., et al. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
20. Pfeiffer, C. D., et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
21. Sirohi, B., et al. 2006. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 38:47-51. (Pubitemid 43923089)
22. Smith, P. B., et al. 2009. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr. Infect. Dis. J. 28:412-415.